FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Drug, Device Violations in Sale of OTC Asthmanefrin

[ Price : $8.95]

FDAs Florida District Office warns Nephron Pharmaceuticals that its Asthmanefrin is an unapproved new drug being marketed inapprop...

Multiple QS Violations at German Epflex Firm

[ Price : $8.95]

FDA warns Germans Epflex Feinwerktechnik about Quality System Regulation violations in its manufacturing of guidewire devices.

United Therapeutics Backs Actelion Generic Ventavis Petition

[ Price : $8.95]

United Therapeutics tells FDA it supports Actelions petition asking that any generic Ventavis be approved with a nebulizer that ha...

Guidance on Early Feasibility Device Studies

[ Price : $8.95]

Federal Register Notice: FDA releases a guidance: Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Cl...

Guidance on ANDA Submissions Standards

[ Price : $8.95]

Federal Register Notice: FDA releases a draft guidance: ANDA Submissions Refuse-to-Receive Standards.

Like the Phoenix, Pay-for Device Inspections Rise from the Ashes?

[ Price : $8.95]

Former FDA district director John Scharmann says CDRHs plan to pilot pay-for third-party inspections in January is likely to be as...

Vertex sNDA for Kalydeco Expanded Indication

[ Price : $8.95]

Vertex Pharmaceuticals files a supplemental NDA for Kalydeco (ivacaftor) monotherapy for people with cystic fibrosis aged six and ...

CDER Guidance on ANDA Refuse-to-Receive Criteria

[ Price : $8.95]

CDER releases a draft guidance on ANDA Submissions ― Refuse-to-Receive Standards that describes what should be included in a...

FDA to Retain 8,000 (55%) of its Staff Under Shutdown Plan

[ Price : $8.95]

Absent some miraculous compromise on Capitol Hill, it appears a government shutdown affecting almost half of FDA personnel is like...

FDA Accelerated Approval for Genentechs Perjeta

[ Price : $8.95]

FDA grants accelerated approval to Genentech for Perjeta (pertuzumab) and its use as part of a complete treatment regimen for pati...